Keywords: EMEA, Tysabri, Elan, Biogen, GlaxoSmithKline, Arepanrix, Arzerra, Flu vaccines, Tamiflu
EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products
Article | 22 January 2010
The European Medicines Agency (EMEA) has finalized a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus, saying the drug continues to outweigh risks for patients with highly active relapsing-remitting multiple sclerosis who have few options for alternative treatment.
T Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
